[
    [
        {
            "time": "",
            "original_text": "【中银医药】博雅生物收购资产点评：拟并入疫苗优质资产，罗益未来三年复合增速25%",
            "features": {
                "keywords": [
                    "博雅生物",
                    "收购",
                    "疫苗",
                    "优质资产",
                    "罗益",
                    "复合增速",
                    "25%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【中银医药】博雅生物收购资产点评：拟并入疫苗优质资产，罗益未来三年复合增速25%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]